Bandhan Small Cap Fund
The Scheme seeks to generate long term capital appreciation by investing predominantly in equities and equity linked securities of small cap segment.
Growthvine rating: 5/5 — ranked #1 of 37 in category.
Fund basics
| Category | Equity: Small Cap |
|---|
| NAV | ₹51.49 (as of 2026-11-13) |
|---|
| AUM | ₹35,856 Cr |
|---|
| Expense ratio | 1.32% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Kirthi Jain |
|---|
| Exit load | 1% for redemption within 365 days |
|---|
Performance & risk
| 5-year annualised return | 16.63% |
|---|
| Sharpe ratio | 0.71 |
|---|
| Standard deviation | 20.92% |
|---|
| Max drawdown | −25.20% |
|---|
| Alpha | 8.22 |
|---|
| Beta | 0.93 |
|---|
Over 5 years, captured 97.7% of NIFTY Smallcap 250's upside and 80.1% of its downside.
Market cap allocation
| Large cap | 9.7% |
|---|
| Mid cap | 11.2% |
|---|
| Small cap | 79.2% |
|---|
Concentration
| Top 5 holdings | 11.2% |
|---|
| Top 10 holdings | 19.8% |
|---|
| Total holdings | 267 |
|---|
| Index overlap | 18.4% |
|---|
| Active share | 81.6% |
|---|
Top holdings
- Triparty Repo TRP_021126_VAL — 8.9%
- Sobha Limited — 2.6%
- State Bank Of India — 2.3%
- CHOLAMANDALAM FINANCIAL HOLDINGS LIMITED — 2.3%
- REC LIMITED — 2.1%
- HDFC Bank Ltd. — 2.0%
- LT Foods Limited — 1.9%
- South Indian Bank Ltd. — 1.9%
- Cyient Limited — 1.8%
- JUBILANT PHARMOVA LIMITED — 1.6%
Top sectors
- Banking & Financial — 20.0%
- Cash — 8.7%
- Pharma & Biotech — 7.6%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | 11.0% | Q3 | #18 of 34 |
| 2025 | −1.1% | Q1 (Top) | #7 of 30 |
| 2024 | 43.1% | Q1 (Top) | #2 of 28 |
| 2023 | 53.6% | Q1 (Top) | #2 of 24 |
| 2022 | −6.1% | Q4 (Bottom) | #21 of 22 |